



Express Mail No.: EV475141382US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Andrew J. Dannenberg et al. Confirmation No.: 5777

Application No.: 10/680,606

Group Art Unit: 1614

Filed: October 7, 2003

Examiner: Rebecca Cook

For: INHIBITION OF
CYCLOOXYGENASE-2
ACTIVITY

Attorney Docket No.: 9516-203-999
(Formerly 1129-207.1)
(CAM:501872-999202)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This responds to the Office Action mailed July 6, 2005 which sets forth a Restriction Requirement. Petition for extension of time is submitted herewith with authorization to charge any required fee to extend the time for a response for a month to and including September 6, 2005.

REMARKS

A Restriction Requirement under 35 U.S.C. §121 has been entered in the present application. The Restriction Requirement identifies two groups:

Group I: Claims 1-4, drawn to a method of treating inflammatory disease, classified in class 514 and subclass 231.5; and

Group II: Claims 5-15, drawn to a method of inhibiting angiogenesis and treating cancer, classified in class 514 and subclass 231.5.

Applicants respectfully traverse the restriction requirement and submit that a search related to methods for treatments comprising the administration of the compounds of the present claims would not impose an undue burden on the Examiner. In particular, any search directed to the recited compounds would necessarily uncover any uses thereof. Further, both Groups are in the same class and subclass, indicating no lack of unity. Thus, Applicants respectfully request that Groups I and II be examined collectively.